Docsity
Docsity

Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity


Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan


Guidelines and tips
Guidelines and tips

Diagnosis and Management of Nursing Home Acquired Pneumonia: A Guideline, Lecture notes of Nursing

Information on the diagnosis and management of Nursing Home Acquired Pneumonia (NHAP), including definitions, issues, goals, prevention, diagnosis, and background. It covers topics such as exclusions, definitions, symptoms, diagnosis criteria, prevention methods, and treatment options. The guideline is administered by the Alberta Medical Association.

What you will learn

  • What are the issues related to the diagnosis and management of Nursing Home Acquired Pneumonia?
  • What are the exclusions for Nursing Home Acquired Pneumonia?
  • What are the goals for the diagnosis and management of Nursing Home Acquired Pneumonia?
  • What are the prevention methods for Nursing Home Acquired Pneumonia?
  • What are the definitions of Nursing Home Acquired Pneumonia?

Typology: Lecture notes

2021/2022

Uploaded on 09/12/2022

lalitlallit
lalitlallit 🇺🇸

4.1

(10)

226 documents

1 / 11

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
This clinical practice guideline (CPG) was developed by
an Alberta CPG Working Group.
EXCLUSIONS
♦ Hospital acquired pneumonia (onset within 14
days of discharge from an acute care facility)
♦ Aspiration pneumonia (see Appendix 1)
♦ Patients with cystic fibrosis, tuberculosis, or
bronchiectasis
DEFINITIONS
♦ Pneumonia in a patient residing in a nursing
home*
* This applies to any congrgate residential setting for
older and disabled patients that have high personal and
professional care needs. These are sometimes known as
long term care facilities, auxiliary hospitals, chronic
care centres, or continuing care centres.
ISSUES
♦ Treatment for NHAP should take into account
the individual’s personal directives
♦ There is a lack of well designed studies in this
patient population
♦ Chest radiography is not widely available or
practical in many locations
♦ Microbiologic diagnosis of NHAP has
significant limitations and as such, treatment
of NHAP is usually empiric
♦ Delay in administration of antibiotics for the
empiric treatment of NHAP may lead to in-
creased patient morbidity and mortality
♦ Inappropriate use of antibiotics may adversely
affect patient outcomes and may increase anti-
microbial resistance
Guideline for
The Diagnosis and Management of
Nursing Home Acquired Pneumonia (NHAP)
Administered by the Alberta
Medical Association
GOALS
♦ To enhance an earlier detection and treatment of
NHAP
♦ To increase the accuracy of the clinical diagnosis
of NHAP
♦ To optimise the appropriate use of laboratory and
diagnostic imaging services
♦ To optimise the use of antibiotics in the treatment
of NHAP
♦ To foster teamwork in the evaluation and manage-
ment of patients with NHAP
♦ To optimise the decision for patient transfer to
hospital
♦ To improve patient outcomes through decreased
morbidity and mortality.
PrEvENTION
♦ Limit the spread of infections (e.g., hand washing
and attention to outbreak management guidelines)
♦ Influenza and pneumococcal vaccines are recom-
mended (see Appendix 2)
♦ Smoking cessation and avoidance of environ-
mental tobacco smoke
DIAGNOSIS
Although a new infiltrate seen on chest X-ray with
compatible clinical signs is the gold standard for the
diagnosis of NHAP, in nursing home settings the
diagnosis must often be made on clinical grounds
alone. The physical examination must include blood
pressure, heart rate, respiratory rate and auscultation
of the respiratory system.
The above recommendations are systematically developed statements to assist practitioner and
patient decisions about appropriate health care for specific clinical circumstances.
They should be used as an adjunct to sound clinical decision making.
2008 Update
pf3
pf4
pf5
pf8
pf9
pfa

Partial preview of the text

Download Diagnosis and Management of Nursing Home Acquired Pneumonia: A Guideline and more Lecture notes Nursing in PDF only on Docsity!

This clinical practice guideline (CPG) was developed by an Alberta CPG Working Group.

EXCLUSIONS

♦ Hospital acquired pneumonia (onset within 14 days of discharge from an acute care facility) ♦ Aspiration pneumonia (see Appendix 1) ♦ Patients with cystic fibrosis, tuberculosis, or bronchiectasis

DEFINITIONS

♦ Pneumonia in a patient residing in a nursing home* _ This applies to any congrgate residential setting for older and disabled patients that have high personal and professional care needs. These are sometimes known as long term care facilities, auxiliary hospitals, chronic care centres, or continuing care centres._*

ISSUES

♦ Treatment for NHAP should take into account the individual’s personal directives ♦ There is a lack of well designed studies in this patient population ♦ Chest radiography is not widely available or practical in many locations ♦ Microbiologic diagnosis of NHAP has significant limitations and as such, treatment of NHAP is usually empiric ♦ Delay in administration of antibiotics for the empiric treatment of NHAP may lead to in- creased patient morbidity and mortality ♦ Inappropriate use of antibiotics may adversely affect patient outcomes and may increase anti- microbial resistance

Guideline for

The Diagnosis and Management of

Nursing Home Acquired Pneumonia (NHAP)

Administered by the Alberta Medical Association

GOALS

♦ To enhance an earlier detection and treatment of NHAP ♦ To increase the accuracy of the clinical diagnosis of NHAP ♦ To optimise the appropriate use of laboratory and diagnostic imaging services ♦ To optimise the use of antibiotics in the treatment of NHAP ♦ To foster teamwork in the evaluation and manage- ment of patients with NHAP ♦ To optimise the decision for patient transfer to hospital ♦ To improve patient outcomes through decreased morbidity and mortality.

PrEvENTION

♦ Limit the spread of infections (e.g., hand washing and attention to outbreak management guidelines) ♦ Influenza and pneumococcal vaccines are recom- mended (see Appendix 2) ♦ Smoking cessation and avoidance of environ- mental tobacco smoke

DIAGNOSIS

Although a new infiltrate seen on chest X-ray with compatible clinical signs is the gold standard for the diagnosis of NHAP, in nursing home settings the diagnosis must often be made on clinical grounds alone. The physical examination must include blood pressure, heart rate, respiratory rate and auscultation of the respiratory system. The above recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making.

2008 Update

Symptoms & Signs Cluster If chest X-ray is not available, tachypnea and at least 1 of the following signs and symptoms should be present to make a diagnosis of probable NHAP ♦ Ideally the diagnosis of pneumonia should be sup- ported with chest X-ray, oxygen saturation, complete blood count and differential, blood cultures, and spu- tum cultures. As these tests are frequently unavailable in the nursing home setting, refer to management below. Note: There is still value in performing these tests even after treatment has been initiated. MANAGEMENT Assessment ♦ Determine the degree of medical treatment desired by the patient or legal decision maker such as a guardian or agent named in an enacted personal directive. ♦ Review vital signs

  • Consider transfer to hospital if impending respi- ratory failure or hemodynamic compromise ♦ Oxygenation
  • Oxygen therapy is indicated for hypoxemia (e. g., O 2 <90%)
  • If oxymetry is not available consider oxygen at 2 litres/minute Note: COPD baseline oxygenation may be lower and therefore must be individually assessed ♦ Antibiotic therapy (see Table 1)
  • Ideally antibiotic therapy should be initiated as soon as possible (within 4 hours) after diagnosis and prior to transfer Note: Initiation of antibiotics after 8 hours is associated with an increased mortality
  • Parenteral (IM) treatment may be considered if patient unable to swallow ♦ Hydration
  • Ensure adequate hydration (1 litre in a 24 hour period is required to replace insensible losses under most circumstances). Note: Consider hypodermoclysis Note: Fluid requirement for older persons without cardiac or renal failure is 30ml/kg/day in addition to estimated fluid deficit. Practice Point In the presence of the above signs &/or symptoms administration of antibiotics should NOT be delayed pending the results of any diagnostic tests Tachypnea
  • Most important clinical predictive factor
  • Respiratory rate ≥ 25 is associated with increased morbidity and mortality
  • Respiratory rate ≥ 40 may be an indication for transfer to hospital Notes:Respiratory rate must be counted for a full minute An elevated respiratory rate has a high sensitivity and specificity for the diagnosis of pneumonia. AND AT LEAST ONE OF THE FOLLOWINGFever
  • Temperature of 37.8 C or greater is both a sensitive and specific predictor of infection (positive pre- dictive value of 55% in nursing home residents)
  • Elderly patients have lower basal body tempera- ture therefore fever may be present when the temperature >1.5ºC higher than baseline. Note: Rigors are an important marker for bacteremia.Cough
  • New productive cough is an importantclinical symptom
  • Unproductive cough is not uncommon in this patient population ♦ Pleuritic chest pain
  • Pleuritic chest pain is a specific sign for pneu- monia (also watch for pulmonary embolus) ♦ Crackles, wheezes or bronchial breath sounds
  • New or increased ♦ New onset delirium and/or decreased level of consciousness, increased confusion
  • Sensitive but not specific for pneumonia. ♦ DyspneaTachycardiaNew or worsening hypoxemia

BACKGrOUND Introduction Nursing home-acquired pneumonia (NHAP) is defined as pneumonia occurring in a resident of a Long Term Care (LTC) facility. Prevalence ranges between 1.1 to 2.5% in chronic care facilities^1 , has an incidence of 13 - 48% of all LTC infections and is a common cause for transfer to hos- pital.^2 Lower respiratory tract infections and pneumonia are very common infectious disorders in LTC facilities.^3 In one region 8% of all transfers to hospital were diagnosed in the emergency department with pneumonia, 20% of whom were transferred back to LTC for further treatment.^4 NHAP mortality may be as high as 44%.^5 Higher mortality rates ( two to threefold) distinguishes NHAP from CAP. NHAP was first described in 1978.^6 Since then there has been much written regarding NHAP and its management but there has been a lack of well-designed studies in this patient population.^7 In the absence of randomized controlled trial data for empiric drug therapy, many clinicians have extrapolated findings from community acquired pneumonia (CAP) clinical pathways and guidelines.^8 There is little, if any, evidence to support the application of CAP guide- lines to nursing homes primarily due to advanced patient age and disease complexity in the risk stratification proc- ess. Recent work by Loeb and colleagues in Ontario have demonstrated that the use of a clincal pathway reduced the number of transfers to hospital and had comparable clinical outcomes to a ‘usual’ treatment group.^9 LTC is a unique health care delivery setting with many, often complex, considerations when it comes to clinical decision-making. There are few guidelines that exist to assist physicians in prescribing for LTC patients.^10 The following key elements impact the assessment and man- agement of NHAP in this setting. risk Factors Nursing home patients have lower levels of functioning, are at an advanced age and have significant co-morbid conditions, e.g., COPD, dementia and atherosclerotic heart disease. Other risk factors identified for death from nursing home acquired pneumonia include aspiration, bed-fast state, cerebrovascular accident, difficulty with oropharyngeal secreations, dysphagia, feeding tube, frailty, incontinence, and sedative hypnotic use. Decision-making The high prevalence of dementing illness in LTC is a further limitation on good and reliable decision-making. Many patients and families do not wish to pursue life supporting or life prolonging therapies. In LTC, palliative treatment options are often preferred overaggressive life supporting therapies. Understanding a patient’s wishes is General Management ♦ Analgesics/antipyretics for pain and fever ♦ Cough suppressants are not routinely recommended CONTINUING MANAGEMENT ♦ In the nursing home setting, the care team needs to be involved in daily assessments to alert the physician to significant changes in patient status:

  • Mobility
  • Hydration:
    • 1 litre/day
  • Nutrition:
    • weight loss of >5-10% is related to increased morbidity (Significant weight loss in the nursing home >5% in 30 days or >10% in 6 months)
  • Review medication profile and consider holding or adjusting dosage where appropriate:
    • psychoactive drugs, including hypnotic sedative drugs
    • cardiovascular drugs
  • Review antibiotic treatments at 48 to 72 hours for evidence of response to therapy:
    • temperature stabilization
    • lower respiratory rate ♦ If failure of therapy occurs, consider change in antibiotics or transfer to hospital if:
  • Hemodynamic compromise
  • Clinical deterioration after 72 hours of antibiotic therapy
  • No improvement after completion of antibiotic therapy ♦ Consider:
  • Host-related factors:
  • non-infectious pulmonary pathology
  • immunosuppression
  • Pathogen-related factors
  • antibiotic resistance
  • Non-bacterial etiology
  • viruses
  • Mycobacterium spp
  • fungi
  • Drug-related factors
  • adherence
  • malabsorption
  • drug-drug interactions
  • drug fever

often very challenging and it is imperative that all health care professionals understand how decisions are made regarding individual patient care. It is important that every effort is made to determine a patient’s wishes regarding treatment. An enacted personal directive will greatly assist health care providers make the correct decisions where the patient is unable to direct care. Etiology and pathophysiology The microbiological demographics in LTC are not well understood and will vary between centres. Streptococcus pneumoniae (S. pneumoniae) is recognized as the most common organism in NHAP. One recent prospective study found a prevalance of 55% in patients transferred to hospi- tal with NHAP.^11 There are concerns with the development of penicillin resistant S. pneumoniae and the true preva- lance of atypical pathogens is not known. NHAP more closely resembles community-acquired pneumonia (CAP) than nosocomial pneumonia.The pathophysiology of NHAP is the same as for CAP. The most common pathogens are S. pneumoniae, H. influenzae and M. catarrhalis. Less common pathogens in NHAP are Legionella and Chlamydophilia pneumoniae , although C. pneumoniae is emerging as a pathogen in NHAP. Elderly patients are also more likely to be colonized with gram-negative organisms (especially if decreased functional status, institutionalized and multiple co-morbid illnesses). Tuberculosis (TB) should always be considered (espe- cially in the elderly) given that there is a 10 to 30 times increased incidence of TB in long term care residents. LTC residents account for 20% of all TB cases in older people.12,1^ There is a need to be mindful of TB admission screening findings such as old TB on chest X-ray or Mantoux testing results. Anerobes are not important pathogens in CAP. Although the elderly and patients in LTC have a higher incidence of aspiration, the role of anaerobes in this setting remains controversial. Anaerobic coverage is not recommended in NHAP unless there is severe periodontal disease, putrid sputum, or evidence of necrotizing pneumonia or lung abscess.^13 In up to 50% of cases, a viral infection precedes the development of pneumonia and undoubtedly plays a role in the pathogenesis of pneumonia.14,15^ Viruses may inhibit important host defences, including ciliary activity, neu- trophil function, and other lung defence mechanisms.^15 Cigarette smoke compromises mucociliary function and macrophage activity. Alcohol impairs the cough reflex, increases oropharyngeal colonization with gram-negative bacilli, and may inhibit immune mechanisms.^15 Elderly pa- tients are at increased risk of developing pneumonia due to multiple factors: increased number and severity of co morbidities, decreased mucociliary clearance, diminished cough reflex, increased aspiration, increased colonisation with gram-negatives, and depressed immune system.^15 Differential Diagnosis The most common causes of diagnostic confusion in this population are non-infectious cardiac and pulmonary disorders. Congestive heart failure (CHF) is a common disorder resembling NHAP. CHF may represent an exac- erbation of a pre-existing CHF resulting in shortness of breath for the patient thus resembling the presentation of NHAP. It may also co-exist with NHAP. Chest radiographs are the best way to diagnose NHAP. Patients with NHAP have segmental or lobar distribution of infiltrates as seen on chest X-rays. Patients with CHF will have a redistribution of vasculature to the upper lobes, usually accompanied by cardiomegaly. Pre-existing chest X-rays may reveal previous interstitial lung disease that can be confused with the appearance of NHAP. Fever of 38OC or more accompanied by pulmonary symp- toms suggests NHAP, especially when accompanied by a productive cough. However, in elderly patients, the febrile response may be blunted. Thus, the absence of fever is unhelpful in making the differential diagnosis. Pleural effusions can also cause diagnostic confusion in the diagnosis of pneumonia. Bacterial pneumonias, particu- larly due to S. pneumoniae and H. influenzae , may be ac- companied by pleural effusion. Pleural effusions without associated infiltrates are not pneumonia. Diagnosis Diagnosis of pneumonia is based on a patient’s history, co-morbidities, physical findings, and chest X-ray. Symp- toms of NHAP most commonly include fever, chills, dys- pnea, pleuritic chest pain, and cough. With increasing age, symptoms of infection may not be as apparent and physical signs may be diminished. Fever may be less commonly observed but delirium and confusion may be more common in this population. Delirium or acute confusion is found in 44.5% of elderly patients with pneumonia.^16 Tachypnea is the only physical sign for which a predictive value can be calculated for LTC residents. Normal respira- tory rate in the elderly is 16 to 25 breaths per minute.^10 A respiratory rate of > 25 breaths per minute has a sensitivity of 90% and a specificity of 95% for the diagnosis of pneu- monia.^17

Amoxicillin This provides very effective activity against S. pneumoniae even in cases of high level resistance to penicillin. Macrolide A macrolide may be added if there is underlying lung dis- ease such as COPD or in severe pneumonia. Macrolides are also effective against atypical pneumonia such as Chlamydophilia pneumoniae , Mycoplasma pneumoniae or Legionella. However, macrolide resistance in S. pneumo- niae exceeds 10% and coverage of Haemophilus spp may not be optimal. Azithromycin has no appreciable serum concentrations and should not be used in patients with rigors/chills as this may indicate bacteremia. Cefuroxime May be considered in cases of penicillin allergy or post influenza pneumonia where Staph aureus may be a potential pathogen. Doxycycline S. pneumoniae resistance is known to be low (Capital Health authority 5%) and makes this an excellent choice. Many physicians have reported excellent clinical results using doxycycline in the management of NHAP. Respiratory fluoroquinolones Levofloxacin and moxifloxacin provide excellent coverage of the pathogens involved, but because of their broad spectrum and potential for increasing resistance in S. pneumoniae , they should be reserved for patients who 1) have failed first line therapy or 2) are elderly and have co morbidities. Ciprofloxacin does not have adequate coverage of S. pneumoniae and should not be used in the management of NHAP. Antibiotic resistance has become a significant issue among US nursing homes. Heavy utilization of the fluo- roquinolone group of antibiotics has contributed to the development of resistance due to their widespread empiric use.^27 Antibiotic resistant organisms are currently felt to be a less significant issue in Canadian centres due in large part to the restricted use of fluoroquinolones. Hospitalisation Thirty-three out of 1000 nursing home residents are hospi- talised with NHAP versus 1.14 per 1000 population who require hospitalisation due to CAP.^14 For patients with NHAP, referral to acute care for a more supported treatment environment should be considered in the following circumstances:

  • Respiratory distress (e.g. respiratory rate over 40)
  • Tachycardia (pulse over 125)
  • CHF
  • Systolic BP less than 90mmHg
  • Signs of impending hemodynamic instability
  • Signs of respiratory failure
  • Reduced level of consciousness
  • Clinical judgement of the attending physician at any time
  • Level of acuity that cannot be managed at the facility
  • Limited capacity to support the illness at the facility e.g. oxygen not available. All patients diagnosed with NHAP should receive oral or parenteral antibiotics within 4 to 8 hours of diagnosis. Even those patients that require admission to hospital for treatment of pneumonia. If antibiotic therapy is delayed for more than 8 hours, the mortality rate is much higher than if antibiotics are given within 8 hours.^28 Recovery is often prolonged in the elderly and may take up to several months. Hospitalization of this population may often hasten functional decline. Continuing Management In the LTC setting key management teams should be in- volved in the daily reassessment of patients. The monitor- ing of vital signs and the communication of changes in vital signs are key to successful NHAP management. This requires the involvement of nursing, pharmacy, dietitians, occupational therapy and physiotherapy staff to monitor mobility, eating and response to antibiotics. Medication profiles need to be reviewed as often as the need for psy- choactive medication changes during an acute infectious disease such as NHAP. Prevention
  • Smoking cessation and avoidance of environmental to- bacco smoke. Smoking is the strongest independent risk factor for invasive pneumococcal disease in adults.^22
  • Limit the spread of viral infections (e.g., hand washing). Hand washing can prevent up to 80% of the most common infectious diseases (mostly viral) which may predispose to pneumonia.
  • Influenza vaccine is recommended annually for high risk patients (see Appendix 2)
  • Pneumococcal vaccine is recommended for high risk patients (see Appendix 2)
  • Rehabilitation (occupational therapy and/or physi- otherapy) and nutritional programs where appropriate

rEFErENCES

  1. Marrie T. Community acquired pneumonia in the elderly. Clin Infect Dis, 2000 Oct; 31(4): 1066-1078.
  2. Muder AR, Brennan C, Serenson D, Wagener M. Pneumonia in a long term care facility: a prospective study of outcome. Arch Intern Med, 1996; 156: 2365-2370.
  3. Nicolle L, McIntyre M, Zacharias H, et al. Twelve month surveillance of infections in institutionalized elderly men. J Am Geriatr Soc, 1984 July; 32(7): 513-519.
  4. Utilization Improvement Project Care Centre Leaves. Calgary Health Region, 1999
  5. Naughton B, Mylotte J, Tayara A. Outcome of Nursing Home Acquired Pneumonia: Derivation and Application of a practical model to predict 30 day mortality. J Am Geriatr Soc, 2000; 48: 1292-1299. 6 Garb J, Brown R, Garb JR, Tuthill R. Differences in etiology of pneumonias in nursing home and community patients. JAMA, 1978 Nov; 240(20): 2169-2172.
  6. Mylotte J Nursing Home Acquired Pneumonia Drugs Aging 2006;23(5):377-
  7. Marrie T, Lau C, Wheeler S. A controlled trial of a clinical pathway for treatment of community acquired pneumonia. JAMA 2000; 283: 749-755.
  8. Loeb M Carusone S, Goeree R et al Effect of a Clinical Pathway to Reduce Hospitilizations in Nursing Home Residents with Pneumonia. JAMA. 2006.295: 2503-
  9. McGeer A. Antibiotic use in continuing care. A short sighted view that needs correction. Drug Use in the Elderly, 1998 Jan; 17.
  10. Lim WS, Macfarlane JT A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia Eur Respir J 2001;18: 362-368.
  11. Narain J, Lofgren J, Warren E, Stead W. Epidemic tuberculosis in a nursing home: a retrospective cohort study. J Am Geriatr Soc, 1985; 33: 258-262.
  12. Marik P. Aspiration pneumonitis and aspiration pneumonia. NEJM, 2001; 344:665-671.
  13. Mandell L, Marrie T, Grossman R, et al. Canadian guidelines for the initial management of community acquired pneumonia: an evidence based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis, 2000; 31: 383-421.
  14. Marrie T. Treating community acquired pneumonia in elderly women: disease severity dictates optimal management approach. Women’s Health in Primary Care, Jan 2001; 4(1): 84-96.
  15. Riquieleme R, Torres A, el-Ebiary M, et al. Community acquired pneumonia in the elderly. Clinical and nutritional aspects. Am J Respir Crit Care Med, 1997; 156: 1908-1914.
    1. McFadden JP, Eastwood HD, Briggs RS Raised respiratory rate in elderly dehydrated patients Clin Endocrinol 1984;20:626-
    2. Bentley D. Bacterial pneumonia in the elderly: clinical features, diagnosis, etiology and treatment. Gerontology, 1984; 30: 297-307.
    3. Castle S, Norman D, Miller D, Yoshikawa T. Fever response in elderly nursing home residents: are the older truly colder? J Am Geriatr Soc 1991 Sep;39(9):853-857.
    4. Wasserman M, et al. Utility of fever, white blood cells and differential count in predicting bacterial infections in the elderly. J Am Geriatric Soc, 1989; 37: 537-43.
    5. Geckler R, Gremillion D, McAllister C, Ellenbogen C. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J Clin Microbiol, Oct 1977; 6(4):396-399.
    6. Arbo M, Snydman D. Influence of blood culture results on antibiotic choice in the treatment of bacteremia.Arch Intern Med 1994 Dec 12- 26;154(23):2641-
    7. Fine M, Smith M, Carson C, et al. Efficacy of pneumococcal vaccination in adults: a meta analysis of randomized controlled trials. Arch Intern Med, 1994; 154: 2666-2677.
    8. Houck P Bratzler D Administration of first hospital antibiotics for community-acquired pneumonia: does timeliness affect otucomes? Curr Opin Infect Dis 18:151-156.
    9. Degelau J, Guay D, Straub K. Effectiveness of oral antibiotic treatment in nursing home acquired pneumonia. J. Am Geriatr Soc, 1995; 43: 245-251.
    10. Fried T, Gillick M, Lipsitz L. Whether to transfer? Factors associated with hospitalisation and outcomes in elderly long term care patients with pneumonia. J Gen Intern Med, 1995; 10: 246-250.
    11. Bonomo R. Multiple antibiotic resistant bacteria in long term care facilities: an emerging problem in the practice of infectious diseases. Clin Infect Dis, 2000; 31:1414-1422.
    12. Meehan T, Fine M, Krumholz H, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA, 1997; 278: 2080-2084.
    13. Blondel-Hill E, Fryters S. Bugs and Drugs: Antimicrobial Pocket Reference, 2006. Capital Health Authority, Edmonton.
    14. Canada Communicable Diseases Report 2000; 26(ACS02):1-15.
    15. Canada Immunization Guide - Health Canada, 5th edi- tion, 1998.
    16. Communication from Disease Control and Prevention - Alberta Health, October 1998.

APPENDIX 1: ASPIrATION PNEUMONIA^29 Definitions

  • Aspiration pneumonitis : chemical injury caused by the inhalation of gastric contents, resulting in inflammatory reaction. No antibiotic therapy recommended in aspiration pneumonitis
  • Aspiration pneumonia: development of radiographically evident infiltrate following the aspiration of colonized oropharyngeal material risk Factors for Aspiration Pneumonia
  • Decreased level of consciousness
  • Dysphagia
  • Anatomic abnormality of the upper GI tract
  • Mechanical interference of the GI tract (ET/NG tubes) Clinical Picture
  • Usually older patient with above risk factors
  • Infiltrates in dependent lung segments, especially RLL
  • Episode of aspiration often not witnessed
  • May progress to abscess/empyema within 1-2 weeks Etiology
  • Role of anaerobes is controversial
  • Gram stain may be helpful in diagnosis and decision to use anti-anaerobic therapy
  • Choice of antibiotic dependent on clinical situation
    • Cefuroxime has good activity against most oral anaerobes Prevention
  • Bedside swallowing assessment and modified barium swallow if indicated
  • Staff education to identify residents at risk or with dysphagia
  • Ensure appropriate diet and liquid consistency
  • Address positioning issues eg hyper-extended neck
  • Ensure upright position with meals and tube feeds
  • Routine dental evaluations and oral hygiene especially in patients with xerostomia
  • Treatment of xerostomia Usual Pathogens Nursing Home Acquired S. pneumoniae H. influenzae S. aureus Enterobacteraceae^1 Nursing Home Acquired with poor oral hygiene/severe periodontal disease S. pneumoniae H. influenzae S. aureus Enterobacteraceae^1 Oral anaerobes Streptococci spp Eikenella corrodens recommended Therapy and Dose Cefuroxime IV/PO 750mg IV q8h/500mg PO bid OR Levofloxacin 500mg PO daily Amoxicillin-clavulanate 875mg PO bid OR Cefuroxime IV/PO 750mg IV q8h/500mg PO bid PLUS Metronidazole IV/PO 500mg IV/PO q12h OR Levofloxacin 500mg PO daily PLUS Metronidazole IV/PO 500mg IV/PO q12h Duration 10 days 10 days 10-14 days^2 10-14 days^2 10-14 days^2 Comments
  1. Alcoholism and enteral feeding may be risk factors for colonization with these organisms
  2. If x-ray evidence of necrotizing pneumonia or abscess, treat for 3 to 6 weeks

APPENDIX 2: INFLUENZA AND PNEUMOCOCCAL vACCINES30- Influenza vaccine should be given annually to: High risk:

  • Adults and children with chronic cardiac or pulmonary disorders (bronchopulmonary dysplasia, cystic fibrosis, asthma)
  • Adults and children with chronic conditions: diabetes and other metabolic diseases, cancer, immunodeficiency (including HIV), immunosuppression (including renal transplants), renal disease, anemia, hemoglobinopathy
  • Residents of nursing homes or long term care facilities
  • People ≥ 65 years of age
  • Children and adolescents treated with long term ASA
  • People at high risk of influenza complications travelling to foreign destinations where influenza is likely to be circulating People capable of transmitting influenza to those at high risk:
  • Health care workers and other personnel who have continuous, direct care contact with people in high risk groups (above)
  • Household contacts (including children) of people at high risk who cannot be immunized or are immunosuppressed or elderly/frail Others:
  • People who provide essential community services and other adults who wish to reduce their chances of acquir- ing infection and consequently missing work
  • Pregnant women in high risk groups (vaccine is considered safe for pregnant women, regardless of stage of pregnancy) Protection begins 2 weeks post vaccination and lasts up to 6 months (may be less in the elderly). Pneumococcal polysaccharide vaccine Strongly recommended - High risk:*
    • Asplenia (traumatic/surgical/congenital)
    • Splenic dysfunction
    • Sickle-cell disease Notes Where possible give vaccine 10 to 14 days prior to splenectomy or at beginning of chemotherapy for Hodgkin’s disease. _ Vaccine failures may occur in this group - advise counselling (re: fulminant pneumococcal sepsis and need_* to seek early medical advise with fever). recommended:
    • All persons ≥ 65 years old
    • All residents of long term care facilities
    • Patients with chronic cardiovascular/pulmonary disease, cirrhosis, alcoholism, chronic renal disease, diabetes mellitus, HIV infection, and other conditions associated with immunosuppression, chronic cerebrospinal fluid leak. Note: Vaccine may be administered simultaneously with influenza vaccine (separate injection site). Not recommended:
    • Children < 2 years of age
    • Asthma (as the single underlying condition)
    • Otitis media (as the single underlying condition)
    • Severe allergy to any component of the vaccine.